Investigating the effects of antidepressants on measures of insulin resistance in major depressive disorder: A systematic review

This publication has 65 references indexed in Scilit:

• Serotonin (5‐Hydroxytryptamine): Metabolism, Signaling, Biological Functions, Diseases, and Emerging Therapeutic Opportunities
  Medcomm, 2025
• Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions
  World Psychiatry, 2023
• Fluoxetine ameliorates high-fat diet-induced metabolic abnormalities partially via reduced adipose triglyceride lipase-mediated adipocyte lipolysis
  Biomedicine & Pharmacotherapy, 2021
• Antidepressant Medications and Weight Change: A Narrative Review
  Obesity, 2020
• Brain insulin resistance: A treatment target for cognitive impairment and anhedonia in depression
  Experimental Neurology, 2019
• Impact of Muscarinic M3 Receptor Antagonism on the Risk of Type 2 Diabetes in Antidepressant-Treated Patients: A Case-Controlled Study
  CNS Drugs, 2017
• Antidepressants versus placebo in major depression: an overview
  World Psychiatry, 2015
• Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD
  European Neuropsychopharmacology, 2009
• Comparisons of glucose–insulin homeostasis following maprotiline and fluoxetine treatment in depressed males
  Journal of Affective Disorders, 2007
• Comparison of Fluoxetine and Paroxetine in Type II Diabetes Mellitus Patients
  Archives of Medical Research, 2005